Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 25;25(5):2661.
doi: 10.3390/ijms25052661.

Liquid Biopsy: A Game Changer for Type 2 Diabetes

Gratiela Gradisteanu Pircalabioru  1   2   3 , Madalina Musat  1   4   5 , Viviana Elian  6   7 , Ciprian Iliescu  1   3   8
Affiliations
Review

Liquid Biopsy: A Game Changer for Type 2 Diabetes

Gratiela Gradisteanu Pircalabioru et al. Int J Mol Sci. .

Abstract

As the burden of type 2 diabetes (T2D) continues to escalate globally, there is a growing need for novel, less-invasive biomarkers capable of early diabetes detection and monitoring of disease progression. Liquid biopsy, recognized for its minimally invasive nature, is increasingly being applied beyond oncology, and nevertheless shows its potential when the collection of the tissue biopsy is not possible. This diagnostic approach involves utilizing liquid biopsy markers such as cell-free nucleic acids, extracellular vesicles, and diverse metabolites for the molecular diagnosis of T2D and its related complications. In this context, we thoroughly examine recent developments in T2D liquid biopsy research. Additionally, we discuss the primary challenges and future prospects of employing liquid biopsy in the management of T2D. Prognosis, diagnosis and monitoring of T2D through liquid biopsy could be a game-changing technique for personalized diabetes management.

Keywords: exosomes; liquid biopsy; miRNA; molecular diagnostic; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Liquid biopsy markers in T2D. Liquid biopsies encompass a diverse range of clinically informative elements. Blood samples can undergo analysis for metabolites, exosomes, and cell-free nucleic acids, each offering valuable numerical and molecular insights. Employment of liquid biopsy in T2D patients can provide valuable insight regarding T2D complications, cardiovascular disease (CVD), and cancer risk. Figure created using biorender.com.
Figure 2
Figure 2
Diagram illustrating the processes involved in the generation of microvesicles, exosomes, and apoptotic bodies.
See this image and copyright information in PMC

References

    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. Ignatiadis M., Sledge G.W., Jeffrey S.S. Liquid biopsy enters the clinic—Implementation issues and future challenges. Nat. Rev. Clin. Oncol. 2021;18:297–312. doi: 10.1038/s41571-020-00457-x. - DOI - PubMed
    1. Iliescu F.S., Poenar D.P., Yu F., Ni M., Chan K.H., Cima I., Taylor H.K., Cima I., Iliescu C. Recent advances in microfluidic methods in cancer liquid biopsy. Biomicrofluidics. 2019;13:041503. doi: 10.1063/1.5087690. - DOI - PMC - PubMed
    1. Yaghoubi Naei V., Bordhan P., Mirakhorli F., Khorrami M., Shrestha J., Nazari H., Kulasinghe A., Ebrahimi Warkiani M. Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA. Ther. Adv. Med. Oncol. 2023;15:17588359231192401. doi: 10.1177/17588359231192401. - DOI - PMC - PubMed
    1. Armakolas A., Kotsari M., Koskinas J. Liquid Biopsies, Novel Approaches and Future Directions. Cancers. 2023;15:1579. doi: 10.3390/cancers15051579. - DOI - PMC - PubMed

MeSH terms